Mylan pharma insider trading security trading scheme of material nonpublic inside info, FDA drug approvals, financial earnings, and amerger with a Pfizer, Ramkumar Rayapureddy Mylan's CIO, provided info to co consiprator Dayakar Mallu,to execute trades in the company’s securities
/PRNewswire/ First-Quarter 2022 Results Reflect Strong Operational Start to the Year Total Revenues Were $4.19 billion U.S. GAAP Net Earnings Were $399.2.
Following the completion of the spin-off of the Upjohn Business
(4) in the fourth quarter of 2020, Pfizer now operates as a focused innovative biopharmaceutical company engaged in the discovery, development, manufacturing, marketing, sales and distribution of biopharmaceutical products worldwide.
Revenues and expenses associated with the Upjohn Business
(4) for first-quarter 2020 have been recategorized as discontinued operations and excluded from Adjusted
(2) results. Pfizer’s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, which had been reported within the results of the Upjohn Business
(4) in the first three quarters of 2020
, is now included within the Hospital therapeutic area for all periods presented.